Date: 2011-09-13
Type of information: R&D agreement
Compound: biophysics research services in the area of hit matter discovery and characterization
Company: Zobio (The Netherlands) Abbott (USA)
Therapeutic area:
Type agreement: R&D
services
Action mechanism:
Disease: undisclosed
Details: Abbott and ZoBio have reached an agreement whereby ZoBio will supply a variety of biophysics research services to Abbott in the area of hit matter discovery and characterization. Amongst the services to be provided, ZoBio will use its proprietary TINS technology for ligand discovery on a variety of targets designated by Abbott. TINS (Target Immobilised Nuclear Magnetic Resonance Screening platform) is a proprietary technology that combines the robust NMR approach with extreme sensitivity to very weak interactions such as those between a drug fragment and a target.
Orthogonal validation will be provided through ZoBio’s Biacore instrumentation. This combination of technologies is unique in the field and is part of what attracted Abbott to ZoBio.
Financial terms: Financial terms were not disclosed.
Latest news:
